NIOSHTIC-2 Publications Search

Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides.

Biagini RE; Schlottmann SA; Sammons DL; Smith JP; Snawder JC; Striley CAF; MacKenzie BA; Weissman DN

Clin Diagn Lab Immunol 2003 Sep; 10(5):744-750

https://doi.org/10.1128/CDLI.10.5.744-750.2003

20023573

We describe a fluorescent covalent microsphere immunoassay (FCMIA) method for the simultaneous (multiplexed) measurement of immunoglobulin G (IgG) antibodies to 23 pneumococcal capsular polysaccharide (PnPS) serotypes present in the pneumococcal polysaccharide vaccine (PPV23) licensed by the Food and Drug Administration, i.e., PnPSs 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. In addition, the assay incorporates an internal control that allows for contemporaneous evaluation of the effectiveness of pneumococcal cell wall polysaccharide (C-PS) preadsorption and a second control of PnPS 25 (which is not present in any polysaccharide or conjugate vaccine), which can be used to evaluate interassay reproducibility (useful for pre- versus postvaccination studies). The FCMIA was standardized with U.S. reference antipneumococcal serotype standard serum 89S-2. Preadsorption of 89S-2 with each PnPS and C-PS yielded homologous inhibition for serotypes 1, 6B, 9N, 9V, 11A, 12F,14, 15B, 18C, 19A, 19F, 20, 22F, 25, and 33F; heterologous inhibition for serotypes 9V, 10A, 11A, 12F, 15B, 17F, 20, and 23F; and neither homologous nor heterologous inhibition for serotypes 2, 3, 4, and 5. The minimum detectable concentrations for the 24 multiplexed (PnPS and C-PS) FCMIAs ranged from 20 pg/ml for PnPS 3 to 600 pg/ml for PnPS 14. The PnPS FCMIA method has numerous benefits over enzyme-linked immunosorbent assays commonly used to measure anti-PnPS-specific IgG levels, including increased speed, smaller sample volumes, equivalent or better sensitivity, and increased dynamic range.

Polysaccharides; Sampling; Vaccines; Immunotoxins; Bioassays; Serology; Proteins; Antibody response; Immunological tests; Immunoglobulins; Enzyme activity; Enzymes; Laboratory testing; Biological monitoring

Raymond E. Biagini, Division of Applied Research and Technology, National Institute for Occupational Safety and Health, MS-C26, 4676 Columbia Parkway, Cincinnati, OH 45226

CDIMEN

20030901

Journal Article

reb4@cdc.gov

2003

5

1071-412X

HELD; DART

Clinical and Diagnostic Laboratory Immunology

OH; WV